PharmacoEconomics - Open

2017 - 2026

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 10, issue 4, 2026

Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop pp. 593-608

R. Brett McQueen, Benjamin Cohen, Caroline Kacergis, Eileen Kennedy and Katherine L. Rosettie

Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies pp. 609-621

Bezie Kebede, Bereket Bahiru and Chernet Tafere

Trial-Based Economic Evaluations Conducted alongside Studies Embedded in Australian Healthcare Services and Programs: A Scoping Review pp. 623-645

Belinda Wang, Catherine Sherrington, Luiza R. Pivotto, Stanley Saputra, Josielli Comachio, Joanne Scarfe, Zoe Szewczyk, Nathalia Costa, Alison Pearce, Leanne Hassett, Andrew Milat, Christopher Williams, Wing S. Kwok, Justin Yu, Kirsten Howard and Marina B. Pinheiro

Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of Obesity pp. 647-659

Ben Modley, Ahmed Seddik, Marc Evans, Stephanie Stephens, Chloe Salter and Marilena Appierto

Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal pp. 661-677

Eleftherios Zarkadoulas, Fábio Silva, Joana Alves, Francisco Madeira and Maarten J Postma

Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer pp. 679-694

Yancy S. Wu, Emily A. Burger, Fredrik Holmboe, Magnus Bangum, Francisco Oteiza, Christoffer Bugge, Erik Magnus Sæther and Eline Aas

Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China pp. 695-706

Tongming Zhu, Kunkun Ge, Aizong Shen and Yingqi Wu

Estimating Eligibility for Lung Cancer Screening in Ireland: A Dynamic Modelling Study of Smoking Trends pp. 707-720

Tatiana Bezdenezhnykh, James F. O’Mahony, Benjamin M. Jacob and Patrick Redmond

Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness Study pp. 721-731

Zhi Zhen Lim, Yan Ling Lim, Furene Sijia Wang, Simon Robert Ling, Stacey Kiat Hong Tay and Yi Wang

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis pp. 733-748

Jeanine Flanigan, Sarah Kane, Fatemeh Mirzayeh Fashami, Anna Zhou, Lamees Almuallem, Mike Tindal, Marion Schauf, Edward Li and Gary H. Lyman

A Micro-costing Study of Community-Based Primary HPV Self-Sampling and Triage Test for Cervical Cancer Screening in Rural Cambodia pp. 749-758

Ziyue Zhang, Hermann Bussmann, Sathiarany Vong, Hero Kol, Magnus von Knebel Doeberitz, Manuela De Allegri and Kavita Singh

Updated Health Economics Simulation Model of the Lifetime Progression of Multiple Sclerosis in an Australian Setting pp. 759-767

Andrew J. Palmer, Ting Zhao, Glen Henson, Hasnat Ahmad, Bruce V. Taylor, Ingrid van der Mei and Julie A. Campbell

Prediction Error in Quality-Adjusted Life Years in Economic Evaluations of Immune Checkpoint Inhibitors: A Comparison Based on Projected and Observed Updated Survival pp. 769-779

Jinyu Chen, Yichen Zhang, Kexin Han, Sheng Han, Luwen Shi and Xiaodong Guan

Volume 10, issue 3, 2026

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs pp. 393-406

Mario García-Díaz, Jorge Mestre-Ferrándiz and Jaime Espín

Health Utilities Associated with Pneumococcal Diseases in Children and Adults: A Targeted Literature Review and Meta-analysis pp. 407-422

Min Huang, Hela Romdhani, Yan Song, Jipan Xie, Sanjana Sundaresan, Daisy Liu, Donna Rowen, Elamin H. Elbasha, Salini Mohanty and Matthew S. Kelly

Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations pp. 423-455

Alyssa Grant, Dima Kabbani, Andrew Vuong, Becky Skidmore, Amy T. Hsu, Geetha Sanmugalingham, Rienk de Vries, Sherrie Logan, Patricia Gongal, Caroline C. Piotrowski and Kednapa Thavorn

Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States pp. 457-469

Ahmead Baljoon, Vakaramoko Diaby, Sandra Suther, Matthew Dutton, Askal Ali and Islam Eljilany

Comparative Cost-Effectiveness Analysis of Multiple First-Line Treatments for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer in Japan pp. 471-489

Kosuke Morimoto, Kensuke Moriwaki, Yoshitaka Nishikawa, Tomomi Maeda, Mayumi Toyama, Nobukazu Agatsuma, Satomi Kojima, Takahiro Utsumi, Yoshimitsu Takahashi, Kojiro Shimozuma and Takeo Nakayama

Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis pp. 491-501

Mena Scavina, Nate Posner, Patricia Dorling, Anna Talaga, Anna Stachel and Jose Alvir

Exploring the Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI3, 15D, AQoL-4D, and AQoL-8D Multi-Attribute Utility Instruments to SF-36 Dimensions pp. 503-518

Josephine N. A. Tetteh and Michael Schlander

Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France pp. 519-529

Samir Hamamah, Jeremy Carette, Henri Leleu and Marie Markert

Understanding the Humanistic Burden of Metabolic Dysfunction-Associated Steatohepatitis Liver Disease in the US Population: Age/Sex Stratified Analysis of Morbidity and Mortality pp. 531-541

Andrew H Briggs, Ziyi Lin, Daniel Aggio, Villum Wittrup-Jensen, Salvador Augustin, John Schneider and Andrew Lloyd

Valuing Maintenance of Visual Function in Retinitis Pigmentosa: A Discrete Choice Experiment with Patients and the General Public pp. 543-555

Kevin Marsh, Myrto Trapali, Mike Ingham and Silas Martin

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? pp. 557-566

Iago Rodríguez-Lago, José Ignacio Peinado-Fabregat, Marcelo Guigini, Mónica Cerezales, Francisco Ibáñez, Carlos Crespo and Manuel Barreiro- de Acosta

Prevalence and Healthcare Costs of Metabolic Disorders Among Individuals with Schizophrenia Following Initiation of Oral Antipsychotic Therapy pp. 567-575

Joseph Tkacz, Alejandro Cajigal, Matthew Sidovar, Kathleen Wilson, Emma Pennington, Ilya Okunev and Kristin Gillard

A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care pp. 577-588

Masood Moghul, Deokhee Yi, Fionnuala Croft, Fiona Mutch, Elisabeth Westaway, Netty Kinsella, Patrick Kierkegaard, Declan Cahill and Nicholas David James

Correction: Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis pp. 589-589

Mena Scavina, Nate Posner, Patricia Dorling, Anna Talaga, Anna Stachel and Jose Alvir

Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn’s Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? pp. 591-591

Iago Rodríguez-Lago, José Ignacio Peinado-Fabregat, Marcelo Guigini, Mónica Cerezales, Francisco Ibáñez, Carlos Crespo and Manuel Barreiro- de Acosta

Volume 10, issue 2, 2026

Retractions of Health Economic Evaluations: A Systematic Review pp. 215-227

Eric Julian Manalastas, Aditi Hombali, Juliette C. Thompson and David Alexander Scott

Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal pp. 229-247

Thi Hao Pham, Jovan Mihajlović, Ivan Loncar, Ba Khuong Cao, Florian Zeevat, Thanh An Pham, Abrham Wondimu, Kinga Meszaros and Jurjen van der Schans

Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective pp. 249-263

Sam Harper, Khanh Ha Bui, Stuart Mealing, Daniel Sanchez, Pablo Priego Jiménez and Carlos Moreno Sanz

Healthcare Cost Associated with an Acute Mental Healthcare Bundle in Pediatric Emergency Departments pp. 265-274

Lola Ibraimova, Amanda S. Newton, Stephen B. Freedman, Jennifer Thull-Freedman, Bruce Wright, Arto Ohinmaa and Dat T. Tran

Potential Economic Value of Multi-cancer Early Detection Testing Under Differential Cost Trends for Cancer Screening and Management pp. 275-287

Anuraag R. Kansal, Ali Tafazzoli, Weicheng Ye, Walter Morris, Denise Zou, Bruce Quinn and A. Mark Fendrick

Economic Evaluation of NHS England’s Type 2 Diabetes Path to Remission Pilot Scheme: Evidence From Real-World Data and Patient Simulation Modelling pp. 289-304

Adam Martin, Tayamika Zabula, Davide Tebaldi, Miaoqing Yang, Tamara Brown and Louisa Ells

Societal Economic Burden of Antibiotic Resistance in Uganda: A Cost of Illness Study pp. 305-316

Elly Nuwamanya, Jonathan Mayito, Stephen Okoboi, Ronald Galiwango, Dathan Byonanebye, Suzan Nakasendwa, Flavia Dhikusooka, Janet Nabisere, Vivian Twemanye, Conrad Tumwine, Mackline Hope, Reuben Kiggundu, Ellon Twinomuhwezi, Lumbwe Chola, Joseph Babigumira, Thorkild Tylleskär, Francis Kakooza and Andrew Kambugu

Impact of Inhibitor Development on the Cost Effectiveness of Prophylactic Treatment with Recombinant Factor VIII in Previously Untreated Patients with Severe Hemophilia A pp. 317-329

Li Yang, Jie Peng, Congling Gu, Zhenguo Wang and Genyong Zuo

Budget Impact of the LungFlag™ Predictive Risk Model for Lung Cancer Screening pp. 331-339

Carolina Heuser, Michael K. Gould, Eran Choman, Nicolò Olghi, Sarika Ogale and Milan Obradovic

Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa pp. 341-354

Louis S. Matza, Timothy A. Howell, Qiaoyi Zhang and Tom Denee

Cost Comparison of Repeat Placental Growth Factor-Based Testing in Women with Suspected Preterm Pre-eclampsia, Compared to Usual Care: The PARROT-2 Trial pp. 355-364

Alice Hurrell, Louise Webster, Jenie Sparkes, Cheryl Battersby, Katherine Clark, Kate E Duhig, Marcus Green, Paul T Seed, Zoe Vowles, Jenny Myers, Andrew H Shennan, Lucy C Chappell and Rachael M Hunter

Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost Neutrality pp. 365-379

Arendse Tange Larsen, Liza Sopina, Eske Kvanner Aasvang, Christian S. Meyhoff, Søren Rud Kristensen and Jakob Kjellberg

Cost Analysis of Immunoglobulin Maintenance Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy in Spain pp. 381-391

Sofía de Pedro, María Presa, Josep Gamez, Francisco Javier Gómez Fernández and Luis Querol

Volume 10, issue 1, 2026

Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews pp. 5-33

Min Huang, Jipan Xie, Hela Romdhani, Yan Song, Sun Lee, Daisy Liu, Elamin Elbasha, Salini Mohanty, Donna Rowen and Matthew S. Kelly

Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review pp. 35-51

Nishma Patel, Suzanne Farid and Manuel Gomes

Cost of Chronic Heart Failure Among Adult Europeans—A Systematic Literature Review pp. 53-69

Alexandra Mincă, Claudiu C. Popescu, Dragoş I. Mincă, Amalia L. Călinoiu, Adina Rusu, Ana Ciobanu, Valeriu Gheorghiţă and Dana G. Mincă

Model-Based Economic Analyses of Haemophilia from a Societal Perspective: A Scoping Review pp. 71-95

Amr A. El-Sayed and Nancy S. Bolous

The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland pp. 97-108

Xiang Wang, Feili Zhao, David Newby, Lan Gao and Shuchuen Li

Individual Preference for Fecal Immunochemical Test Options among Younger Adults: A Discrete Choice Experiment pp. 109-120

Kailu Wang, Ho-Man Shum, Carrie Ho-Kwan Yam, Shangfeng Tang, Chunyan Li, Yushan Wu, Eliza Lai-Yi Wong and Eng-Kiong Yeoh

Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain pp. 121-142

Iago Rodríguez-Lago, Fernando Muñoz Núñez, Alfredo J. Lucendo, Alfonso De Lossada Juste, Ana Cabez, Alberto de la Cuadra-Grande, Itziar Oyagüez and Emilio Monte-Boquet

Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer pp. 143-152

Aylin Sertkaya, Zeid El-Kilani, Sean Klein, Andreas Lord, Ruben Jacobo-Rubio and Sonal Parasrampuria

Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis pp. 153-165

Gijs van de Wetering, Carolyn Owen, Versha Banerji, Ariane Gosselin, Shivani Kamdar, Nancy Paul Roc, Lytske Bakker, Gargi Ratnaparkhi, Stephane Barakat, Colin Vicente and Beenish S. Manzoor

Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study pp. 167-178

Xinran Liu, Chang Luo, Shitong Xie and Jing Wu

Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment pp. 179-196

Tobias Sydendal Grand, Shijie Ren, Praveen Thokala, Stefano Zanigni, Daniel Oudin Åström, Aroussi Bidani, Günter Höglinger, Werner Poewe, Florian Krismer and Stephane Regnier

Estimation of Health Utility Values for Eosinophilic Granulomatosis With Polyangiitis pp. 197-207

Bhovina Buguth, Jacqui Bernarde, Daniel Aggio, Arya Pimprikar, Michael Watt, Lotte Westerink, Josefine Persson and Andrew Lloyd

Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain pp. 209-213

Rosa María Romero Jiménez, Pedro Herranz Pinto, Minia Campos Domínguez, Alba Bellmunt, Neus Vidal-Vilar, María del Pilar Fortes Soto and Alfonso De Lossada Juste